RETRACTED: Zhou et al. Pyrvinium Treatment Confers Hepatic Metabolic Benefits via β-Catenin Downregulation and AMPK Activation. <i>Pharmaceutics</i> 2021, <i>13</i>, 330
The authors and the journal retract the article, ‘Pyrvinium Treatment Confers Hepatic Metabolic Benefits via β-Catenin Downregulation and AMPK Activation’ [...]
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-05-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/15/6/1623 |
| _version_ | 1797593087022727168 |
|---|---|
| author | Shiwei Zhou Obinna N. Obianom Jiangsheng Huang Dong Guo Hong Yang Qing Li Yan Shu |
| author_facet | Shiwei Zhou Obinna N. Obianom Jiangsheng Huang Dong Guo Hong Yang Qing Li Yan Shu |
| author_sort | Shiwei Zhou |
| collection | DOAJ |
| description | The authors and the journal retract the article, ‘Pyrvinium Treatment Confers Hepatic Metabolic Benefits via β-Catenin Downregulation and AMPK Activation’ [...] |
| first_indexed | 2024-03-11T02:03:48Z |
| format | Article |
| id | doaj.art-f8feec583d7b44c480883805690575f3 |
| institution | Directory Open Access Journal |
| issn | 1999-4923 |
| language | English |
| last_indexed | 2024-03-11T02:03:48Z |
| publishDate | 2023-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceutics |
| spelling | doaj.art-f8feec583d7b44c480883805690575f32023-11-18T12:04:07ZengMDPI AGPharmaceutics1999-49232023-05-01156162310.3390/pharmaceutics15061623RETRACTED: Zhou et al. Pyrvinium Treatment Confers Hepatic Metabolic Benefits via β-Catenin Downregulation and AMPK Activation. <i>Pharmaceutics</i> 2021, <i>13</i>, 330Shiwei Zhou0Obinna N. Obianom1Jiangsheng Huang2Dong Guo3Hong Yang4Qing Li5Yan Shu6Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, ChinaDepartment of Pharmaceutical Sciences, School of Pharmacy, University of Maryland, Baltimore, MD 21201, USADepartment of Thyroid Surgery, The Second Xiangya Hospital, Central South University, Changsha 410011, ChinaDepartment of Pharmaceutical Sciences, School of Pharmacy, University of Maryland, Baltimore, MD 21201, USADepartment of Pharmaceutical Sciences, School of Pharmacy, University of Maryland, Baltimore, MD 21201, USADepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, ChinaDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, ChinaThe authors and the journal retract the article, ‘Pyrvinium Treatment Confers Hepatic Metabolic Benefits via β-Catenin Downregulation and AMPK Activation’ [...]https://www.mdpi.com/1999-4923/15/6/1623n/a |
| spellingShingle | Shiwei Zhou Obinna N. Obianom Jiangsheng Huang Dong Guo Hong Yang Qing Li Yan Shu RETRACTED: Zhou et al. Pyrvinium Treatment Confers Hepatic Metabolic Benefits via β-Catenin Downregulation and AMPK Activation. <i>Pharmaceutics</i> 2021, <i>13</i>, 330 Pharmaceutics n/a |
| title | RETRACTED: Zhou et al. Pyrvinium Treatment Confers Hepatic Metabolic Benefits via β-Catenin Downregulation and AMPK Activation. <i>Pharmaceutics</i> 2021, <i>13</i>, 330 |
| title_full | RETRACTED: Zhou et al. Pyrvinium Treatment Confers Hepatic Metabolic Benefits via β-Catenin Downregulation and AMPK Activation. <i>Pharmaceutics</i> 2021, <i>13</i>, 330 |
| title_fullStr | RETRACTED: Zhou et al. Pyrvinium Treatment Confers Hepatic Metabolic Benefits via β-Catenin Downregulation and AMPK Activation. <i>Pharmaceutics</i> 2021, <i>13</i>, 330 |
| title_full_unstemmed | RETRACTED: Zhou et al. Pyrvinium Treatment Confers Hepatic Metabolic Benefits via β-Catenin Downregulation and AMPK Activation. <i>Pharmaceutics</i> 2021, <i>13</i>, 330 |
| title_short | RETRACTED: Zhou et al. Pyrvinium Treatment Confers Hepatic Metabolic Benefits via β-Catenin Downregulation and AMPK Activation. <i>Pharmaceutics</i> 2021, <i>13</i>, 330 |
| title_sort | retracted zhou et al pyrvinium treatment confers hepatic metabolic benefits via β catenin downregulation and ampk activation i pharmaceutics i 2021 i 13 i 330 |
| topic | n/a |
| url | https://www.mdpi.com/1999-4923/15/6/1623 |
| work_keys_str_mv | AT shiweizhou retractedzhouetalpyrviniumtreatmentconfershepaticmetabolicbenefitsviabcatenindownregulationandampkactivationipharmaceuticsi2021i13i330 AT obinnanobianom retractedzhouetalpyrviniumtreatmentconfershepaticmetabolicbenefitsviabcatenindownregulationandampkactivationipharmaceuticsi2021i13i330 AT jiangshenghuang retractedzhouetalpyrviniumtreatmentconfershepaticmetabolicbenefitsviabcatenindownregulationandampkactivationipharmaceuticsi2021i13i330 AT dongguo retractedzhouetalpyrviniumtreatmentconfershepaticmetabolicbenefitsviabcatenindownregulationandampkactivationipharmaceuticsi2021i13i330 AT hongyang retractedzhouetalpyrviniumtreatmentconfershepaticmetabolicbenefitsviabcatenindownregulationandampkactivationipharmaceuticsi2021i13i330 AT qingli retractedzhouetalpyrviniumtreatmentconfershepaticmetabolicbenefitsviabcatenindownregulationandampkactivationipharmaceuticsi2021i13i330 AT yanshu retractedzhouetalpyrviniumtreatmentconfershepaticmetabolicbenefitsviabcatenindownregulationandampkactivationipharmaceuticsi2021i13i330 |